ArticleImmunology2014
Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.
Article in Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 95 citations in OpenAlex.
- Compartment-specific regulation of stromal differentiation of the spleen in health and disease.Genes and immunity · 2026Review
- Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis.medRxiv : the preprint server for health sciences · 2025Article
- A neuro-lymphatic communication guides lymphatic development by CXCL12 and CXCR4 signaling.Development (Cambridge, England) · 2024Article
- Atypical chemokine receptors in the immune system.Nature reviews. Immunology · 2024Review
- Heterogeneous expression of the atypical chemokine receptor ACKR3 in glioblastoma patient-derived tissue samples and cell cultures.Scientific reports · 2024Article
- ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects.Neurochemical research · 2024Article
- The Role of Atypical Chemokine Receptors in Neuroinflammation and Neurodegenerative Disorders.International journal of molecular sciences · 2023Review
- Atlas of the anatomical localization of atypical chemokine receptors in healthy mice.PLoS biology · 2023Article
- New pairings and deorphanization among the atypical chemokine receptor family - physiological and clinical relevance.Frontiers in immunology · 2023Review
- Absence of Nkx2-3 induces ectopic lymphatic endothelial differentiation associated with impaired extramedullary stress hematopoiesis in the spleen.Frontiers in cell and developmental biology · 2023Article
- GPR182 is a broadly scavenging atypical chemokine receptor influencing T-independent immunity.Frontiers in immunology · 2023Article
- Atypical chemokine receptors: emerging therapeutic targets in cancer.Trends in pharmacological sciences · 2022Review
- Endothelial deletion of TBK1 contributes to BRB dysfunction via CXCR4 phosphorylation suppression.Cell death discovery · 2022Article
- Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate.Annals of medicine · 2021Review
- Ackr3-Venus knock-in mouse lights up brain vasculature.Molecular brain · 2021Article
- Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7.ACS pharmacology & translational science · 2021Article
- ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- CXCR4-Binding Positron Emission Tomography Tracers Link Monocyte Recruitment and Endothelial Injury in Murine Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- Lymphatic endothelial-cell expressed ACKR3 is dispensable for postnatal lymphangiogenesis and lymphatic drainage function in mice.PloS one · 2021Article
- CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concentration of CXCL12/SDF-1 in the bloodstream is tightly regulated, given its central role in leucocyte and stem/progenitor cell egress from bone marrow and recruitment to sites of inflammation or injury. The mechanism responsible for this regulation is unknown. Here we show that both genetic deletion and pharmacological inhibition of CXCR7, a high-affinity CXCL12 receptor, caused pronounced increases in plasma CXCL12 levels. The rise in plasma CXCL12 levels was associated with an impairment in the ability of leucocytes to migrate to a local source of CXCL12. Using a set of complementary and highly sensitive techniques, we found that CXCR7 protein is expressed at low levels in multiple organs in both humans and mice. In humans, CXCR7 was detected primarily on venule endothelium and arteriole smooth muscle cells. CXCR7 expression on venule endothelium was also documented in immunodeficient mice and CXCR7(+/lacZ) mice. The vascular expression of CXCR7 therefore gives it immediate access to circulating CXCL12. These studies suggest that endothelial CXCR7 regulates circulating CXCL12 levels and that CXCR7 inhibitors might be used to block CXCL12-mediated cell migration for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.